verastem, inc. (nasdaq: vstm) is a biopharmaceutical company focused on discovering and developing novel drugs that selectively target cancer stem cells. cancer stem cells are an underlying cause of tumor recurrence and metastasis. verastem is translating breakthrough discoveries in cancer stem cell research into new medicines for the treatment of major cancers such as breast cancer. for more information, please visit www.versatem.com
Company profile
Ticker
VSTM
Exchange
Website
CEO
Brian Stuglik
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
273269467
VSTM stock data
Latest filings (excl ownership)
DEF 14A
Definitive proxy
12 Apr 24
8-K
Delivering Novel Therapies in RAS/MAPK Pathway Driven Cancers April 2024 Corporate Presentation
9 Apr 24
S-8
Registration of securities for employees
14 Mar 24
10-K
2023 FY
Annual report
14 Mar 24
SC TO-I/A
Issuer tender offer statement (amended)
11 Mar 24
SC TO-I
Issuer tender offer statement
8 Feb 24
8-K
Regulation FD Disclosure
29 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
19 Jan 24
8-K
Entry into a Material Definitive Agreement
8 Jan 24
DEF 14A
Definitive proxy
19 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 96.77 mm | 96.77 mm | 96.77 mm | 96.77 mm | 96.77 mm | 96.77 mm |
Cash burn (monthly) | 29.19 mm | (no burn) | 7.10 mm | 6.48 mm | 5.53 mm | 6.12 mm |
Cash used (since last report) | 198.11 mm | n/a | 48.21 mm | 44.00 mm | 37.53 mm | 41.52 mm |
Cash remaining | -101.34 mm | n/a | 48.55 mm | 52.76 mm | 59.23 mm | 55.25 mm |
Runway (months of cash) | -3.5 | n/a | 6.8 | 8.1 | 10.7 | 9.0 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 64 |
Opened positions | 16 |
Closed positions | 34 |
Increased positions | 4 |
Reduced positions | 41 |
13F shares | Current |
---|---|
Total value | 118.68 bn |
Total shares | 45.99 mm |
Total puts | 54.31 k |
Total calls | 47.15 k |
Total put/call ratio | 1.2 |
Largest owners | Shares | Value |
---|---|---|
Biotechnology Value Fund L P | 20.09 mm | $0.00 |
1Globe Capital | 4.20 mm | $14.12 mm |
D. E. Shaw & Co | 4.04 mm | $13.57 mm |
Viking Global Investors | 1.89 mm | $14.03 bn |
BVF | 1.69 mm | $12.54 bn |
Deerfield Management | 1.54 mm | $11.45 bn |
Flynn James E | 1.54 mm | $14.95 mm |
Vivo Capital | 1.54 mm | $11.45 bn |
Orbimed Advisors | 1.53 mm | $11.38 bn |
Baker Bros. Advisors | 1.34 mm | $9.94 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Apr 24 | Daniel Calkins | Common Stock | Sell | Dispose S | No | No | 10.87 | 6 | 65.22 | 8,535 |
25 Mar 24 | Daniel Calkins | Common Stock | Sell | Dispose S | No | No | 12.02 | 25 | 300.50 | 8,541 |
20 Mar 24 | Daniel Calkins | Common Stock | Sell | Dispose S | No | No | 11.07 | 55 | 608.85 | 8,566 |
19 Mar 24 | Paterson Dan | Common Stock | Sell | Dispose S | No | No | 10.38 | 182 | 1.89 k | 86,490 |
19 Mar 24 | Stuglik Brian M | Common Stock | Sell | Dispose S | No | No | 10.38 | 273 | 2.83 k | 89,640 |
18 Mar 24 | Paterson Dan | Common Stock | Sell | Dispose S | No | No | 10.71 | 244 | 2.61 k | 86,672 |
18 Mar 24 | Stuglik Brian M | Common Stock | Sell | Dispose S | No | No | 10.71 | 537 | 5.75 k | 89,913 |
News
HC Wainwright & Co. Reiterates Buy on Verastem, Maintains $17.5 Price Target
19 Mar 24
RBC Capital Reiterates Outperform on Verastem, Maintains $32 Price Target
15 Mar 24
Recap: Verastem Q4 Earnings
14 Mar 24
Verastem Q4 2023 Adj EPS $(1.10) Misses $(0.62) Estimate
14 Mar 24
Verastem Oncology Announces Multiple Oral Presentations At Society Of Gynecologic Oncology 2024 Annual Meeting On Women's Cancer
11 Mar 24
Press releases
GenFleet Therapeutics Announces Potent Anti-tumor Efficacy of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, and its Potential in Combination Therapy with RAF/MEK Clamp at 2024 AACR Annual Meeting
9 Apr 24
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4 Apr 24
Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women's Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs
11 Mar 24
Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
5 Mar 24
Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024
5 Mar 24